Positive News SentimentPositive NewsNASDAQ:CDTX Cidara Therapeutics (CDTX) Stock Price, News & Analysis $12.95 -0.01 (-0.08%) (As of 08/29/2024 ET) Add Compare Share Share Today's Range$12.51▼$12.9750-Day Range$11.10▼$13.2452-Week Range$10.00▼$24.40Volume7,538 shsAverage Volume44,486 shsMarket Capitalization$59.08 millionP/E RatioN/ADividend YieldN/APrice Target$29.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Cidara Therapeutics alerts: Email Address Cidara Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.25 Rating ScoreUpside/Downside129.1% Upside$29.67 Price TargetShort InterestHealthy1.61% of Float Sold ShortDividend StrengthN/ASustainability-0.85Upright™ Environmental ScoreNews Sentiment1.88Based on 3 Articles This WeekInsider TradingAcquiring Shares$105,680 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($13.07) to $12.63 Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.63 out of 5 starsMedical Sector89th out of 940 stocksBiological Products, Except Diagnostic Industry12th out of 143 stocks 3.6 Analyst's Opinion Consensus RatingCidara Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.25, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageCidara Therapeutics has only been the subject of 3 research reports in the past 90 days.Read more about Cidara Therapeutics' stock forecast and price target. Previous Next 4.0 Short Interest Percentage of Shares Shorted1.61% of the float of Cidara Therapeutics has been sold short.Short Interest Ratio / Days to CoverCidara Therapeutics has a short interest ratio ("days to cover") of 2.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Cidara Therapeutics has recently decreased by 1.49%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldCidara Therapeutics does not currently pay a dividend.Dividend GrowthCidara Therapeutics does not have a long track record of dividend growth. Previous Next 4.6 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreCidara Therapeutics has received a 72.74% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for infectious diseases", "Preclinical research services for physical health", and "Basic medical research services" products. See details.Environmental SustainabilityThe Environmental Impact score for Cidara Therapeutics is -0.85. Previous Next 3.8 News and Social Media Coverage News SentimentCidara Therapeutics has a news sentiment score of 1.88. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.79 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Cidara Therapeutics this week, compared to 2 articles on an average week.Search Interest1 people have searched for CDTX on MarketBeat in the last 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Cidara Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $105,680.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 7.64% of the stock of Cidara Therapeutics is held by insiders.Percentage Held by InstitutionsOnly 35.82% of the stock of Cidara Therapeutics is held by institutions.Read more about Cidara Therapeutics' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Cidara Therapeutics are expected to grow in the coming year, from ($13.07) to $12.63 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cidara Therapeutics is -1.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cidara Therapeutics is -1.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Read more about Cidara Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Stansberry ResearchBiden’s Big Fix America's Next Nightmare (has nothing to do with November) Roosevelt failed to make it work during World War II. It failed again for Nixon in the ‘70s. Right now, our government is so desperate, they're pulling the same dangerous maneuver... and when it inevitably fails this time, it could tip America into an economic nightmare. It doesn't matter who the Dems select as their nominee – Biden has already set this in motion.Full details here. About Cidara Therapeutics Stock (NASDAQ:CDTX)Cidara Therapeutics, Inc., a biotechnology company, focuses on developing targeted therapies for patients facing cancers and other serious diseases. The company's product includes rezafungin acetate, a novel molecule in the echinocandin class of antifungals for the treatment and prevention of invasive fungal infections, including candidemia and invasive candidiasis, which are fungal infections associated with high mortality rates. It also develops its Cloudbreak platform that enables development of novel drug-Fc conjugates, that includes CD388, a potent antiviral designed to deliver universal prevention and treatment of seasonal and pandemic influenza, which is in Phase 1 and Phase 2a clinical trials. The company was formerly known as K2 Therapeutics, Inc. and changed its name to Cidara Therapeutics, Inc. in July 2014. The company was incorporated in 2012 and is based in San Diego, California.Read More CDTX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart CDTX Stock News HeadlinesAugust 19, 2024 | globenewswire.comCidara Therapeutics Announces Appointment of Jim Beitel as Chief Business OfficerAugust 16, 2024 | msn.comHC Wainwright & Co. Upgrades Cidara Therapeutics (CDTX)August 30, 2024 | Stansberry Research (Ad)Biden’s Big Fix America's Next Nightmare (has nothing to do with November) Roosevelt failed to make it work during World War II. It failed again for Nixon in the ‘70s. Right now, our government is so desperate, they're pulling the same dangerous maneuver... and when it inevitably fails this time, it could tip America into an economic nightmare. It doesn't matter who the Dems select as their nominee – Biden has already set this in motion.August 14, 2024 | finanznachrichten.deCidara Therapeutics, Inc.: Cidara Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial ResultsAugust 13, 2024 | globenewswire.comCidara Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial ResultsJuly 3, 2024 | globenewswire.comCidara Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)May 30, 2024 | globenewswire.comCidara Therapeutics to Present Preclinical Data on CD388 at ASM Microbe 2024 ConferenceMay 16, 2024 | markets.businessinsider.comBuy Rating Justified by Cidara Therapeutics’ Upcoming Clinical Trials and Expanding Oncology PipelineAugust 30, 2024 | Stansberry Research (Ad)Biden’s Big Fix America's Next Nightmare (has nothing to do with November) Roosevelt failed to make it work during World War II. It failed again for Nixon in the ‘70s. Right now, our government is so desperate, they're pulling the same dangerous maneuver... and when it inevitably fails this time, it could tip America into an economic nightmare. It doesn't matter who the Dems select as their nominee – Biden has already set this in motion.May 16, 2024 | finanznachrichten.deCidara Therapeutics, Inc.: Cidara Therapeutics Regains Compliance with Nasdaq Continued Listing RulesMay 16, 2024 | msn.comCDTX Stock Earnings: Cidara Therapeutics Misses EPS, Misses Revenue for Q1 2024May 15, 2024 | stockhouse.comROSEN, A LEADING NATIONAL FIRM, Encourages Cidara Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - CDTXMay 15, 2024 | sfgate.comCidara Therapeutics: Q1 Earnings SnapshotMay 15, 2024 | globenewswire.comCidara Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial ResultsMay 15, 2024 | globenewswire.comCidara Therapeutics Regains Compliance with Nasdaq Continued Listing RulesMay 10, 2024 | prnewswire.comCDTX INVESTOR NOTICE: ROSEN, TOP RANKED INVESTOR COUNSEL, Encourages Cidara Therapeutics, Inc. Investors to Inquire About Securities Class Action Investigation - CDTXApril 26, 2024 | finanznachrichten.deCidara Therapeutics, Inc.: Cidara Therapeutics Announces Presentations Highlighting Phase 1 and Phase 2a Clinical Data on CD388 at ESCMID 2024April 26, 2024 | finance.yahoo.comCidara Therapeutics Announces Presentations Highlighting Phase 1 and Phase 2a Clinical Data on CD388 at ESCMID 2024See More Headlines Receive CDTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cidara Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/10/2021Today8/30/2024Next Earnings (Estimated)11/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:CDTX CUSIPN/A CIK1610618 Webwww.cidara.com Phone(858) 752-6170FaxN/AEmployees90Year FoundedN/APrice Target and Rating Average Stock Price Target$29.67 High Stock Price Target$40.00 Low Stock Price Target$24.00 Potential Upside/Downside+129.1%Consensus RatingBuy Rating Score (0-4)3.25 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($7.68) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-22,930,000.00 Net Margins-73.46% Pretax Margin-77.25% Return on Equity-201.62% Return on Assets-54.25% Debt Debt-to-Equity RatioN/A Current Ratio0.72 Quick Ratio0.60 Sales & Book Value Annual Sales$53.87 million Price / Sales1.10 Cash FlowN/A Price / Cash FlowN/A Book Value($1.82) per share Price / Book-7.12Miscellaneous Outstanding Shares4,562,000Free Float4,213,000Market Cap$59.08 million OptionableOptionable Beta1.01 10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free Report Key ExecutivesDr. Jeffrey L. Stein Ph.D. (Age 69)President, CEO & Executive Director Comp: $603.7kMr. Shane M. Ward (Age 49)Chief Legal Officer,Corporate Secretary & COO Comp: $464.54kDr. Taylor Sandison M.D. (Age 52)M.P.H., Chief Medical Officer Comp: $497kDr. Kevin M. Forrest Ph.D. (Age 47)Founder and Chief Strategy Officer Comp: $333.31kDr. Preetam Shah M.B.A. (Age 51)Ph.D., CFO, Chief Business Officer & Principal Accounting Officer Comp: $577.85kMs. Allison Lewis CCPSPHR, Senior Vice President of People & CultureDr. Leslie Tari Ph.D. (Age 56)Chief Scientific Officer Comp: $845.1kMs. Laura A. NavaltaSenior Vice President of Clinical OperationsDr. Nicole Davarpanah J.D.M.D., Senior VP of Translational Research & DevelopmentMore ExecutivesKey CompetitorsSCYNEXISNASDAQ:SCYXCurisNASDAQ:CRISNeon TherapeuticsNASDAQ:NTGNApplied Genetic TechnologiesNASDAQ:AGTCX4 PharmaceuticalsNASDAQ:XFORView All CompetitorsInsiders & InstitutionsAlethea Capital Management LLCSold 1,518,584 shares on 8/15/2024Ownership: 1.752%Renaissance Technologies LLCSold 2,459,456 shares on 8/9/2024Ownership: 2.094%Jeffrey SteinBought 8,000 shares on 6/7/2024Total: $105,680.00 ($13.21/share)Leslie TariSold 1,051 sharesTotal: $14,083.40 ($13.40/share)Preetam ShahSold 946 sharesTotal: $12,676.40 ($13.40/share)View All Insider TransactionsView All Institutional Transactions CDTX Stock Analysis - Frequently Asked Questions How have CDTX shares performed this year? Cidara Therapeutics' stock was trading at $15.88 on January 1st, 2024. Since then, CDTX stock has decreased by 18.5% and is now trading at $12.95. View the best growth stocks for 2024 here. How were Cidara Therapeutics' earnings last quarter? Cidara Therapeutics, Inc. (NASDAQ:CDTX) released its quarterly earnings results on Wednesday, November, 10th. The biotechnology company reported ($7.40) earnings per share (EPS) for the quarter, missing the consensus estimate of ($7.20) by $0.20. The biotechnology company earned $7.08 million during the quarter, compared to analysts' expectations of $3.62 million. Cidara Therapeutics had a negative net margin of 73.46% and a negative trailing twelve-month return on equity of 201.62%. When did Cidara Therapeutics' stock split? Shares of Cidara Therapeutics reverse split before market open on Wednesday, April 24th 2024. The 1-20 reverse split was announced on Wednesday, April 24th 2024. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, April 24th 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. When did Cidara Therapeutics IPO? Cidara Therapeutics (CDTX) raised $60 million in an initial public offering (IPO) on Wednesday, April 15th 2015. The company issued 4,000,000 shares at a price of $14.00-$16.00 per share. Jefferies and Leerink Partners acted as the underwriters for the IPO and Wedbush PacGrow Life Sciences, Needham and BTIG were co-managers. Who are Cidara Therapeutics' major shareholders? Top institutional investors of Cidara Therapeutics include Renaissance Technologies LLC (2.09%) and Alethea Capital Management LLC (1.75%). Insiders that own company stock include Jeffrey Stein, Taylor Sandison, Leslie Tari, Preetam Shah, Paul Daruwala, Shane Ward, Brady Johnson and Timothy R Franson. View institutional ownership trends. How do I buy shares of Cidara Therapeutics? Shares of CDTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Cidara Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cidara Therapeutics investors own include Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), VBI Vaccines (VBIV), Verastem (VSTM), Dynavax Technologies (DVAX), Micron Technology (MU) and Exelixis (EXEL). This page (NASDAQ:CDTX) was last updated on 8/30/2024 by MarketBeat.com Staff From Our PartnersWhat Is the $7,882 Stimulus Payment 2024?Biden’s government just announced a new government "stimulus program"... And it could hand you a payment fo...Angel Publishing | SponsoredAI expert reveals new Nvidia predictionEveryone’s talking about AI right now, but I’ve been talking about it for years. And now I’ve just released...Brownstone Research | SponsoredPowerful new AI force leaving everyone behindThere’s a powerful new force sweeping through the AI world right now… And if you don’t know what it is… ...Traders Agency | SponsoredFamous Stock Market Bull Issues Rare “Collapse” WarningTilson says we're in the midst of a collapse – unlike any we've seen since 2008. As you'll see, it all cent...Stansberry Research | Sponsored625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredFirst Disruption to $martphones in 15 Years 🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredExposed: 3 CENT Crypto to Explode August 19th?Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredThis Crypto Coin Could 10x FASTER Than BitcoinThe Bitcoin Halving ignited the 2024 boom, and altcoins are primed to SKYROCKET. Last year we tipped off ou...Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cidara Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cidara Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
